NCT04871646View on ClinicalTrials.gov

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314

PHASE3UnknownINTERVENTIONAL
Enrollment

586

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

August 31, 2022

Conditions
COVID-19 Pneumonia
Interventions
DRUG

CKD-314+SOC

CKD-314 is administered intravenously and standard of care is also performed.

DRUG

CKD-314 Placebo+SOC

CKD-314 placebo is administered intravenously and standard of care is also performed..

Trial Locations (1)

Unknown

RECRUITING

Korea University Guro Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY